Weight loss on Wegovy 1.7mg: what the evidence actually shows

What the trial evidence says about progress through the titration steps

The STEP 1 trial enrolled 1,961 adults with obesity and tracked them over 68 weeks on semaglutide 2.4mg alongside lifestyle changes. The headline figure (roughly 15% average body-weight reduction) reflects the full course, but the weight-loss curve in the published data makes clear that progress begins well before the 2.4mg maintenance dose is reached. By the time participants were moving through the intermediate steps, clinically significant reductions were already visible. The 1.7mg step, sitting just below the maintenance dose, is where many people first notice that their appetite feels genuinely different from baseline.

The NHS patient information for semaglutide describes this graduated approach as intentional: starting low and increasing slowly is designed to let the body adjust and to reduce the likelihood of gastrointestinal side effects. That same NHS guidance notes that the therapeutic benefit (the degree of appetite reduction) tends to be lower at earlier steps. So 1.7mg weight loss is real, but it typically falls short of what the 2.4mg maintenance dose delivers over time. People who want to understand how the two doses compare can read the detail on our 1.7mg versus 2.4mg weight loss page.

It is also worth noting that the MHRA has since approved a 7.2mg maintenance dose (the subject of separate clinical trials) which reported around 20.7% average weight loss over 72 weeks. That development does not change the titration pathway; everyone still starts at 0.25mg and progresses step by step. The 7.2mg option is addressed in the full Wegovy overview for context.

Why the 1.7mg step matters more than it gets credit for

A question our prescribers hear most weeks is some version of: "I've been on 1.7mg for a few weeks and the scale has barely moved, should I push to increase sooner?" It is a fair question, and the honest answer is that weight loss at this step is genuinely variable. A handful of factors shape the outcome: how long the person spent at earlier doses, how closely they followed the recommended lower-calorie diet, their baseline weight, and whether they have weight-related conditions such as type 2 diabetes that affect the rate of response.

What the data do not support is skipping through steps quickly in pursuit of faster results. The titration schedule exists partly to manage tolerability, nausea, constipation and stomach discomfort are most common around dose increases, and rushing the timeline tends to worsen them. The full dose guide explains each step and the reasoning behind it. If a dose change feels overdue or a step feels hard to tolerate, that conversation belongs with a prescriber, not a forum.

There is also practical variation between individuals that trial averages smooth over. Someone 20kg above their target who starts at 0.25mg, progresses steadily through 0.5mg and 1mg, and arrives at 1.7mg after four months may already have lost 8–10% of their body weight. Someone starting the same journey at higher baseline weight may see less percentage change at each individual step, even though absolute kilogram losses are similar or greater.

Side effects to know at this dose, and when to act

The side-effect profile at 1.7mg follows the pattern established at lower doses, generally gastrointestinal in nature. Nausea, loose stools, indigestion and burping are the most reported. They tend to peak in the first few days after a dose step-up and ease off within one to two weeks as the body adapts. Not everyone experiences them; many people find 1.7mg no harder than 1mg.

Two signals warrant prompt medical attention rather than watchful waiting. The first is severe stomach pain that spreads toward the back, this can indicate pancreatitis, which the MHRA highlighted in a Drug Safety Update in January 2026 as a known, infrequent but serious risk with GLP-1 medicines. The second is significant dehydration from persistent vomiting or diarrhoea, which can affect kidney function. Both require a call to a GP or 111, not a self-managed dose pause. Suspected side effects can also be reported directly to the MHRA via the Yellow Card scheme.

For people taking oral contraceptives, it is worth being aware that tirzepatide (a different medicine) has a specific pill-absorption caution at each dose increase; semaglutide does not carry the same evidence-based restriction, though discussing contraception with a prescriber remains sensible. Full safety details are in the patient information leaflet that accompanies each pen. Our FAQs address several common side-effect questions.

What comes next: moving to 2.4mg or staying put

For most people following the standard schedule, 1.7mg is a four-week step before reaching the 2.4mg maintenance dose that produced the STEP 1 trial's headline results. The 2.4mg results page sets out what clinical evidence shows at that level. Some people stay at 1.7mg for longer if their prescriber judges that tolerability or clinical response makes that the right call; the SmPC and the prescriber's assessment guide that decision.

If you missed a weekly injection during this step, the timing of when to catch up matters, and the rules differ depending on how many days have passed, this page on missed doses covers the specifics. And if you want to see a broader picture of where Wegovy sits among available weight-management options, the weight-loss treatment overview is a good starting point before deciding what to discuss at a consultation.

Semaglutide is a prescription-only medicine. What happens at any given dose, and whether a change is right for you, is a clinical conversation. If you have not yet been assessed, or if your current treatment is due for review, our prescribers are available seven days a week. Speak to our prescribers to get a same-day clinical review from a GPhC-registered Independent Prescriber.